
Global Biological Therapy Industry
The world biologics industry was worth almost $150 billion in 2010, according to research from BCC Research. The market is expected to record yearly growth of around 10% to reach almost $240 billion by 2015.
Market growth is fuelled by interest in biosimilars, the need to elaborate a superior drug pipeline, a move towards cost-reducing manufacturing technologies and appealing targets against challenging diseases.
Key Market Segments
- The global gene therapy market is benefiting from increasing interest in the development of disease treatment. RNCOS notes that this market holds strong development potential as progress in the field of gene therapy facilitates research into the pathogenesis of diseases. This involves a move from research laboratories to clinical trials, which leads to greater potential for the biotechnology sector. Gene therapy market expansion is expected to be very strong over the coming years, fuelled by interest from biopharma companies focused on the area. Companies are expected to elaborate therapies for disease through on-site research and grow acquired therapies into commercial forms.
- Gene therapy will prove vital to the medical industry to provide a disease-specific approach to developing treatments. The therapeutic applications of gene therapy are expanding to encompass areas like acquired diseases including immunodeficiency syndromes. Growth is strong in the US, the EU, China, Japan and Canada. Cancer treatment is expected to represent the fastest growing segment, followed by infectious diseases such as AIDS.
- The global RNA Interference (RNAi) industry is expected to record 28% yearly growth for the five-year period ending 2015, reports RNCOS. Market growth will be fuelled by greater use of the expertise for functional genomics research, necessary for target validation, drug discovery and drug development.
- The worldwide market for cancer therapies is expected to reach $225 billion by 2017, according to research from Global Industry Analysts. Market expansion will be fuelled by increasing numbers of cancer patients, adoption of new drugs and growing existing drugs. Market growth will also be driven by greater adoption of high-priced biologic therapies in cancer treatment. Medical treatment of cancer includes therapies such as chemotherapy, radiotherapy and gene therapy. The majority of cancer therapies are elaborated using hormones and cytokines, colony stimulating factors, monoclonal antibodies oncolytic viruses, cancer vaccines, antisense oligonucleotides and other approaches. Leading companies in the sector include Takeda Pharmaceutical Company, GlaxoSmithKline, Eli Lilly, Amgen, Hoffmann-La Roche, Janssen Biotech, Sanofi-Aventis, AstraZeneca, Celgene Corporation, Novartis, Genentech and Bristol-Myers Squibb.
Regional Market Share
- The US stem cell market is expected to record yearly growth of 45% between 2011 and 2013, reports RNCOS. The market has recorded strong growth over the past few years with massive investment despite the economic recession. Stem cell technologies and products are giving rise to breakthroughs in the treatment of diseases.
- Improved outcomes from stem cell research are facilitating new treatment developments and helping cut healthcare costs in the overburdened US healthcare system. Stem cell research is playing an important role in drug discovery and innovative developments in the sector. While the use of stem cell related therapies are receiving increasing recognition, ethical issues have not been entirely quelled.
- State funding for stem cell research has helped drive market growth, with strong support coming from state bodies, such as the New York State Stem Cell Science, the California Institute for Regenerative Medicine and the National Institute of Health. Funding has facilitated research and provided sure backing for the industry.
Market Outlook
The global population is rising and ageing, suffering from increasing incidences of disease. Biological therapy represents an area with vast potential for the medical science sector. Due to the high expense of developing and producing biologic treatments, the pressure to reduce prices is growing. The success of the market remains dependent on government funding and approvals by prominent health bodies.
Leading Industry Associations
...More »
» Download Public Reports
About 500 reports
- Company report
- May 2012
- 2 pages
... About osiris therapeutics osiris therapeutics, inc. Is the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic ...
April 2012
... Cell depletion significantly reduced antibody production. Intracellular cytokine staining showed that t cells are a major source of ifn-h9253 and il-10. Recombinant ply and, to a lesser extent, recombinant cbp ...
April 2012
... Novel therapeutic vaccine technology, originating from concepts seeded at the whitehead (mit) Strong ip position Uniquely potent results versus competition Practical, cost effective, therapeutic ...
April 2012
... stem cell technology Genova S approach to fighting cancer is based on the latest discovery in stem cell biotechnology: that cancers grow from stem cells The discovery has changed the way ...
April 2012
... Was developed in il-6h11546/h11546 mice. These results suggest that il-1h9252 and tnf-h9251 play more crucial roles than il-6 or chemokines in this model. Because arthritis was also developed in scid mice ...
April 2012
... Of pain and inflammation as opposed to repairing tissue embryonic stem cell technologies have the potential of being more effective than other cellular approaches - no hypertrophic response is a benefit ...
April 2012
... Sweden) and evry (france) Revenue generated from product sales, r&d collaborations with multinationals as well as grants Currently partner in > 100 m stem cell research programs funded by eu ...
» Purchase Premium Reports
(From $ 100 - $ 4 800)
About 400 reports
- $ 6 000
- Industry report
- March 2012
- by Frost & Sullivan
This research service considers the biologics market in Brazil. It covers the market's move toward greater regulation and outlines the impact of specific patent expirations. An analysis of monoclonal antibodies, ...
April 2012
$ 1 200
In the past few years, gene therapy has come a long way to become one of the most sought after methods to develop a treatment. Despite being at a nascent stage in terms of revenue generation, the gene ...
April 2012
$ 1 200
RNA Interference (RNAi) has emerged as a breakthrough in the life sciences industry. It presents an extensive potential in multiple areas, such as drug discovery, drug development, and therapeutic applications ...
April 2012
$ 910
Bank on it: Innovation and healthcare reform will drive demand for industry services Human Stem Cell Banks Human stem cell banks collect, test, preserve and deliver stem cells from donors either fo ...
April 2012
$ 500
This report provides data on the therapeutic development for Plasma Cell Neoplasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...
April 2012
$ 500
This report provides data on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...
April 2012
$ 500
This report provides data on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...